Clinical Evidence from Dermatology Experts Validates the Therapeutic Value of KeFuMei and KeYu: Genewel Biologics Showcases Recombinant Collagen Breakthroughs at CSD2025

At the recently concluded 30th Annual Conference of Dermatology and Venereology of the Chinese Medical Association (CSD2025),Multiple authoritative dermatology experts have demonstrated the significant clinical value of Comfy and Keyu in the treatment of skin diseases;Meanwhile,Giant Biogene’s Breakthrough Research Progress in the Field of Recombinant CollagenIt has once again received unanimous recognition from the academic community.

As a company deeply rooted in the biotechnology sector, Giant Biogene has been invited to participate in the CSD Conference for consecutive years. This time, it brings its two core strategic brands,six academic posters on recombinant collagen, one thematic satellite symposium, seven academic lectures, and multiple innovative achievements, engaged in in-depth academic exchanges with on-site experts and clinicians, and systematically interpreted Giant Biogene’s solid practices in fulfilling its mission of beauty and health through a comprehensive display covering clinical evidence, technical analysis, scientific research progress, and brand and product portfolio.

The six academic posters presented by Giant Biogene at the CSD Congress were all authored by renowned clinical experts in dermatology. Through clinical observations on the efficacy and safety of recombinant collagen-related products in the adjunctive treatment of psoriasis, infantile hemangioma, and local wound healing, as well as in barrier function recovery after energy-based device procedures and the treatment of sensitive skin, these studies explored their mechanisms of action and provided clinical insights for the management of related conditions.

Studies have found thatRecombinant Collagen for Tissue Repair, Reducing Hyperpigmentation, Skin Barrier Restoration, Soothing, and Moisturizingdemonstrated effective improvements in aspects such as, therebyIn clinical applications, it offers patients better treatment options, shortens healing time, and enhances comfort.。

As a biotechnology company integrating industry, academia, and research, innovative research and technological breakthroughs are equally important. At the Giant Biogene-sponsored satellite symposium during this CSD Congress,Professor Yang Rongya from the Seventh Medical Center of the Chinese PLA General Hospital served as the moderator of the satellite symposium, together with Director Li Xueli from the Medical Aesthetics Center of Henan Provincial People’s Hospital, the Chief Technology Officer of Giant Biogene, and Professor Duan Zhiguang from the Institute of Biomedicine and Pharmaceuticals at Northwest University.engaged in in-depth discussions.

Director Li Xueli, centering on the topic of “The Impact and Intervention of Recombinant Collagen on Skin Barrier Repair After Photoelectric Procedures,” highlighted the excellent clinical application value of recombinant collagen biological repair dressings following photoelectric treatments.

In his report titled “Research Progress on Yeast-Manufactured Low-Immunogenic Recombinant Collagen,” Professor Duan Zhiguang emphasized that the excellent biological functions of recombinant collagen are driving innovative breakthroughs in numerous fields, including dermatology and tissue engineering.

At other thematic satellite symposia held during the conference,Professor Yang Rongya, the Seventh Medical Center of PLA General Hospital; Chen Jin, the First Affiliated Hospital of Chongqing Medical UniversityProfessor, Director Wu Yan of Shengjing Hospital of China Medical UniversityFocusing on key topics such as medical aesthetics, barrier repair, and scar treatment, the session presented clinical case studies of recombinant collagen. Based on these real-world cases, attendees engaged with on-site clinicians in discussions about the broader future application potential of recombinant collagen.

In addition, the Giant Biogene booth also attracted numerous dermatology experts and scholars.Ms. Fang Juan, Senior Vice President of Giant BiogenePresented the company’s latest research advancements to several visiting experts, who highly affirmed Giant Biogene’s pioneering value in its scientific research layout and application translation, while also praising the company’s profound insights into public needs related to beauty and health.

Giant Biogene continues to conduct scientific research in the field of biotechnology, focusing on in-depth exploration of its two core technological ingredients: recombinant collagen and rare ginsenosides. As of December 2024, the company holds 167 patents and patent applications.

Leveraging its deep scientific expertise accumulated through sustained commitment to the recombinant collagen sector, Giant Biogene continues to achieve breakthroughs in the breadth of type coverage, the depth of efficacy exploration, and the rigor of clinical validation, steadily establishing a technology-driven competitive moat.

The two major brands participating in this event, Comfy and Keyu, are both core strategic brands under Giant Biogene, achieving differentiated growth by leveraging the company’s core technological achievements and in-depth scientific research layout.

Comfy: Addressing Skin ConcernsStarting with precise exploration and continuously expanding solutions, we have currently laid out six major product series, including the Comfy Collagen Stick 2.0, which was upgraded and launched in 2025.^[1]and the newly launched Frame Domain Secret Repair series^[2]These products are all derived from consumers' continuously emerging new skincare needs and are launched based on the exclusive patent for novel recombinant Type IV collagen.

Minor Health Issues in Daily LifeDrawing inspiration from multi-touchpoint engagement, the company focuses on the core needs of niche markets, leverages recombinant collagen as its central engine, and synergizes a multi-technology matrix for product development to build a one-stop healthy living toolkit. Its product portfolio spans five major series, including personal beauty and care, facial feature care, and wound care. For instance, the recently launched Keyu Medical Recombinant Collagen Nasal Care Solution starts with safeguarding nasal health, further enriching the brand connotation of Keyu as a “Companion for Healthy Living.”

Ke Fu Mei and Ke Yu, two brands with differentiated positioning, work in synergy to meet the public’s life-health needs and pursuit of quality of life centered on “beauty and health.”

Giant Biogene will remain true to its scientific roots, continuously push the boundaries of research, accelerate the commercialization of scientific achievements, bring science and technology from the laboratory to the public, and let technology meet needs.

Meanwhile, rooted in the forefront of academic discourse, we engage in deep scientific dialogue and collaborate with industry experts to conduct clinical empirical research. Our goal is to deliver tangible benefits to the public, infusing technology with warmth and humanity.

[1] "Comfy Collagen Stick 2.0" is the product nickname; the full product name is Comfy Recombinant Collagen Skin-Barrier Repair Single-Dose Serum.

[2] "Comfy Frame Domain Intensive Repair Series" is the nickname for the product line; the full name of the product line is Comfy Recombinant Collagen Frame Domain Intensive Repair Series.